C4 Therapeutics, Inc. Assets, Fair Value Disclosure
C4 Therapeutics, Inc. (CCCC) had Assets, Fair Value Disclosure of $296.83 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes
us-gaap:AssetsFairValueDisclosure · last filed 2026-02-26
- 2025-12-31: Assets, Fair Value Disclosure $296.83M.
- 2024-12-31: Assets, Fair Value Disclosure $267.03M.
- 2023-12-31: Assets, Fair Value Disclosure $281.52M; Assets, Fair Value Disclosure as first filed $281.22M.
- 2022-12-31: Assets, Fair Value Disclosure $336.87M.
| Period end | Assets, Fair Value Disclosure | Assets, Fair Value Disclosure as first filed |
|---|---|---|
| 2025-12-31 | $296.83M 10-K · filed 2026-02-26 | |
| 2024-12-31 | $267.03M 10-K · filed 2026-02-26 | |
| 2023-12-31 | $281.52M 10-K · filed 2025-02-27 | $281.22M 10-K · filed 2024-02-22 |
| 2022-12-31 | $336.87M 10-K · filed 2024-02-22 | |
| 2022-03-31 | $421.40M 10-Q · filed 2022-05-05 | |
| 2021-12-31 | $451.17M 10-K · filed 2023-02-23 | |
| 2021-09-30 | $479.96M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $498.35M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $345.65M 10-Q · filed 2021-05-13 | |
| 2020-12-31 | $370.04M 10-K · filed 2022-02-24 | |
| 2020-09-30 | $199.41M 10-Q · filed 2020-11-12 | |
| 2019-12-31 | $80.90M 10-K · filed 2021-03-11 | $90.55M 10-Q · filed 2020-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |